Latest Healthcare It News

FOS Capital's subsidiary has landed a $1 million contract for lighting at Monash Medical Clinic, boosting its order book to $10 million and reinforcing its healthcare sector presence.

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

Promisia Healthcare’s aged care occupancy climbed to a record 96% in June 2026, underpinning its FY27 earnings growth guidance. Aldwins House led the turnaround, while solar initiatives and wellness programs roll out across sites.

PainChek announces the immediate departure of CEO Philip Daffas, with COO Andy Hoggan stepping in as interim leader amid a strategic pivot to boost US market growth following FDA clearance.

Stakk Limited is set to become a global powerhouse in AI-driven Digital Trust infrastructure following its US$63 million acquisition of ParaScript, a leader in AI-powered document intelligence and fraud detection. The deal significantly boosts Stakk's scale, technology, and recurring revenue base, underpinning a robust growth trajectory.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.

Enlitic has locked in binding commitments for a conditional A$15 million capital raise alongside a convertible note conversion, setting the stage for a clearer path to cashflow break-even and accelerated rollout of its SaaS platform.

Orthocell has secured a strategic foothold in Thailand's $84 million nerve repair sector by appointing MediTime as exclusive Remplir distributor, leveraging established clinical networks to accelerate market penetration.

OncoSil Medical has submitted its Humanitarian Device Exemption application to the FDA for its OncoSil™ device targeting distal cholangiocarcinoma, entering the final review phase with a decision expected within 45 days.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.